[Newsmp] In July, foreign ownership of pharmaceutical stocks related to COVID-19 treatments decreased significantly.
According to the Korea Exchange, 22 of the 46 pharmaceutical index stocks rose in July, while 22 stocks fell.
Foreign ownership in Ildong Pharmaceutical and Ildong Holdings plunged 4.37%p and 3.10%p, and that of Bukwang Pharmaceutical and Shin Poong Pharmaceutical decreased 1.19%p and 1.06%p, showing that the foreign stake in four stocks retreated by more than 1%p.
A 0.70%p decrease was reported in SK Bioscience and 0.60%p in Korea United Pharm., and foreign ownership of Samjin Pharmaceutical, JW Pharmaceutical, Pharmicell, Kukje Pharma, HanAll Biopharma, Chong Kun Dang Holdings, ORIENTBIO, PharmGen Science, Yungjin Pharm., Il-Yang Pharmaceutical, Reyon Pharmaceutical, Boryung Pharmaceutical, Jeil Pharmaceutical, Kyongbo Pharmaceutical, Ilsung Pharmaceutical, and Daewoong also ramped down.
On the other hand, Daewon Pharmaceutical’s foreign stake rose 1.15%p, Daewoong Pharmaceutical 1.12%p, Yuhan Corporation 0.93%p, Hyundai Pharmaceutical 0.82%p, Hanmi Pharmaceutical 0.80%p, Yuyu Pharma 0.74%p, and CKD Bio 0.54%p, indicating an increase of more than 0.5%p in seven companies.
The foreign ownership of Dong Wha Pharm, Celltrion, Chong Kun Dang Pharmaceutical, Green Cross, Kwang Dong Pharmaceutical, Dong-A ST, Whanin Pharmaceutical, Gene One Life Science, Aprogen Pharmaceuticals, Samsung Pharmaceutical, Samil Pharmaceutical, Handok, Samsung Biologics, Dongsung Pharmaceutical, and Hana Pharm also jumped slightly, and there was no change in Myungmoon Pharmaceutical and JW Life Science.
In the meantime, out of 11 stocks with a foreign stake of more than 10% in the pharmaceutical index, 10 stocks except Il-Yang Pharmaceutical rose during the period.
Green Cross had the highest foreign stake of 22.86%, Celltrion of 20.77%, and Dong-A ST 20.13%, exceeding 20%.
Yuhan Corporation approached the 20% mark with 19.12%, followed by Kwang Dong Pharmaceutical with 18.94%, while Daewon Pharmaceutical, Whanin Pharmaceutical, Hanmi Pharmaceutical, Gene One Life Science, Samsung Biologics, and Il-Yang Pharmaceutical maintained double digits.
